$ALAB

Mazzara Philip sold $232K of ALAB

Mazzara Philip (General Counsel and Secretary) sold 796 shares of Astera Labs, Inc. (ALAB) at $291.03 ($0.23M total) on 2026-05-21.

Original reporting
SEC EDGAR · Mazzara Philip
Published May 26, 2026, 8:44 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALAB
Neutral
medium confidence
Mentioned
$ALAB
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALABNeutralLow
01

Why it matters

The main tradable element is sentiment around insider behavior (selling) rather than any operational or financial update.

02

Market read

Traders may briefly reassess ALAB sentiment due to insider selling, but there is no fundamental company catalyst in the filing details provided.

03

What to watch

Check for clustering of subsequent Form 4s, changes in total insider ownership, and whether the sale coincides with option exercises or vesting-related liquidity needs.

Relevance 6/10Timing: Immediate (new Form 4 filed 2026-05-26; tradeable as a sentiment/positioning signal).

Background

The article is a SEC Form 4 disclosure of an officer’s direct open-market sale of Astera Labs shares.

Company-level read

Ticker impact

$ALABNeutralMedium confidence
Context

Astera Labs (ALAB) disclosed an open-market sale by its General Counsel/Secretary (S) of 796 shares for ~$231.7K on 2026-05-21.

Expected impact

Likely limited near-term impact; any reaction should fade unless follow-on filings show sustained selling.

Evidence & confidence

This is a Form 4 insider transaction (not earnings/M&A/regulatory). The filing notes no pre-arranged 10b5-1 plan, which can increase short-term interpretive risk, but the disclosed size is relatively small and does not indicate a company event.

Market effects

Minimal; single-company insider sale typically does not reset sector fundamentals.

None indicated; US-listed issuer filing only.

None indicated; no cross-border deal/regulatory event mentioned.

Counterpoint

Insider sales can be routine for diversification/taxes; absence of a stated 10b5-1 plan does not necessarily imply negative outlook.

Key entities

  • Astera Labs, Inc.

    Subject of the Form 4 insider transaction; General Counsel/Secretary sold 796 shares for ~$231.7K.

Related articles

$ALABMed

Astera Labs Beat And Guided Higher, Then Fell Because The Rally Came First

Astera Labs (ALAB) reported record fiscal Q2 2026 results, with revenue of $392.4M up 104% year over year, and issued fiscal Q3 2026 guidance of $540M to $560M, above expectations. The stock later fell about 12% after four prior up sessions. The article attributes the shift to product mix, with PCIe 6 and Scorpio switch family ramping, and a non-GAAP gross margin guide down to about 72% from 74%.

$ALABHighAI 9/10

Astera Labs Q2 Earnings Call Highlights

Astera Labs (NASDAQ:ALAB) said on its Q2 earnings call that a lead Scorpio X customer is expected to ramp to high-volume production in Q3, with Scorpio X revenue expected to exceed Scorpio P-Series in that period. Management forecast Q3 revenue of $540 million to $560 million, non-GAAP gross margin about 72%, and non-GAAP EPS of $1.16 to $1.21.

$ALABHighAI 9/10

Astera Labs Q2 Earnings Beat on PCIe 6 and Scorpio Strength

Astera Labs reported Q2 2026 non-GAAP EPS of 80 cents, up 81.8% YoY and 15.94% above the Zacks Consensus. Revenue rose 104.4% YoY to $392.4 million, beating estimates. Management cited PCIe 6 and Scorpio X-Series strength. Q3 guidance calls for $540-$560 million revenue and $1.16-$1.21 non-GAAP EPS.

$ALABMedAI 8/10

ALAB Q2 Earnings Call Puts Scorpio Ramp Ahead of Schedule

Astera Labs (ALAB) said its Q2 2026 results reflected an earlier-than-expected production ramp for Scorpio fabric switches and a planned Q3 revenue step-up. Q3 revenue guidance is $540-$560 million, midpoint 40% sequential growth. Q2 revenue rose to $392.4M, non-GAAP EPS 80 cents, and margins improved.